Description
(AWP Alliance News) - DKSH acquired rights to Roche's antibiotic brand Rocephin across more than 80 markets, expanding its healthcare own-brand portfolio. The brand generated approximately CHF 61 million in net sales in 2025. The acquisition announced on October 28, 2026, strengthens DKSH's position in anti-infectives and follows its purchase of Meliane from Bayer announced in July 2026. Several larger acquired markets overlap with its existing commercial footprint in Asia and Europe.
https://www.publicnow.com/view/DEE380B0411AAFB4CB9B77D6AAAD9E76F24FC876…
Disclaimer: This news brief was created using generative artificial intelligence. DKSH Holding AG published the original content used to generate this news brief via EQS News on October 28, 2026, and is solely responsible for the information contained therein.
